Zai Lab (NASDAQ:ZLAB – Get Free Report) and Anixa Biosciences (NASDAQ:ANIX – Get Free Report) are both healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, profitability, dividends, valuation, earnings, risk and analyst recommendations.
Valuation and Earnings
This table compares Zai Lab and Anixa Biosciences”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Zai Lab | $460.16 million | 6.00 | -$175.54 million | ($1.71) | -14.19 |
| Anixa Biosciences | $210,000.00 | 463.47 | -$10.93 million | ($0.32) | -8.75 |
Profitability
This table compares Zai Lab and Anixa Biosciences’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Zai Lab | -41.86% | -27.43% | -16.72% |
| Anixa Biosciences | N/A | -76.59% | -67.80% |
Insider and Institutional Ownership
41.6% of Zai Lab shares are owned by institutional investors. Comparatively, 29.1% of Anixa Biosciences shares are owned by institutional investors. 4.9% of Zai Lab shares are owned by insiders. Comparatively, 26.4% of Anixa Biosciences shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Risk & Volatility
Zai Lab has a beta of 0.72, suggesting that its share price is 28% less volatile than the S&P 500. Comparatively, Anixa Biosciences has a beta of 0.47, suggesting that its share price is 53% less volatile than the S&P 500.
Analyst Recommendations
This is a breakdown of current recommendations for Zai Lab and Anixa Biosciences, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Zai Lab | 1 | 1 | 4 | 1 | 2.71 |
| Anixa Biosciences | 1 | 1 | 3 | 0 | 2.40 |
Zai Lab currently has a consensus price target of $37.25, suggesting a potential upside of 53.49%. Anixa Biosciences has a consensus price target of $8.00, suggesting a potential upside of 185.71%. Given Anixa Biosciences’ higher probable upside, analysts plainly believe Anixa Biosciences is more favorable than Zai Lab.
Summary
Zai Lab beats Anixa Biosciences on 8 of the 15 factors compared between the two stocks.
About Zai Lab
Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis. The company also develops Tumor Treating Fields, a portable device for delivery of electric fields; Repotrectinib, a tyrosine kinase inhibitor (TKI) to target ROS1 and TRK A/B/C in TKI-naïve- or -pretreated cancer patients; Tisotumab vedotin, an antibody drug conjugate; Adagrasib for treating KRAS-G12C-mutated NSCLC, colorectal cancer, and pancreatic cancer; and Bemarituzumab to treat gastric and gastroesophageal junction cancer patients. In addition, it develops Sulbactam/durlobactam, a combination of a beta-lactam antibiotic and a beta-lactamase inhibitor for the treatment of serious infections caused by Acinetobacter; KarXT for the treatment of psychiatric and neurological conditions. It has license and collaboration agreement with Tesaro, Inc. to develop, manufacture, and commercialize niraparib; NovoCure to develop and commercialize Tumor Treating Fields; Deciphera to develop and commercialize ripretinib; Paratek Bermuda Ltd. to develop, manufacture, and commercialize omadacycline; argenx, to develop and commercialize efgartigimod; BMS to develop and commercialize tisotumab vedotin and repotrectinib; Mirati to research, develop, manufacture, and commercialize adagrasib; Amgen to develop and commercialize bemarituzumab; and Innoviva to develop and commercialize Sulbactam-Durlobactam; Karuna to develop and commercialize KarXT. The company was incorporated in 2013 and is headquartered in Shanghai, China.
About Anixa Biosciences
Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell therapy, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer. Its vaccine programs comprise the development of a vaccine against triple negative breast cancer; and a preventative vaccine against ovarian cancer. The company is also developing immuno-therapy drugs against cancer. The company was formerly known as ITUS Corporation and changed its name to Anixa Biosciences, Inc. in October 2018. Anixa Biosciences, Inc. was incorporated in 1982 and is based in San Jose, California.
Receive News & Ratings for Zai Lab Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zai Lab and related companies with MarketBeat.com's FREE daily email newsletter.
